1-4 of 4
Michelle Chiu
Close
Sort by
Journal Articles

T cell–depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin

Ann A. Jakubowski, Trudy N. Small, James W. Young, Nancy A. Kernan, Hugo Castro-Malaspina, Katherine C. Hsu, Miguel-Angel Perales, Nancy Collins, Christine Cisek, Michelle Chiu, Marcel R. M. van den Brink, Richard J. O'Reilly, Esperanza B. Papadopoulos
Journal: Blood
Blood (2007) 110 (13): 4552–4559.
https://doi.org/10.1182/blood-2007-06-093880
Published: 2007
Journal Articles

Phase II Trial of a Chemotherapy-Only Regimen of Busulfan, Melphalan, Fludarabine and R-ATG Followed by Allogeneic T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplants (HSCT) for the Treatment of Myeloid Malignancies.

Farid Boulad, MD, Ann Jakubowski, MD, Esperanza Papadopoulos, MD, Katharine C. Hsu, MD, Miguel Angel Perales, MD, Marcel van den Brink, MD, James W. Young, MD, Michelle Chiu, Nancy A. Kernan, MD, Susan E. Prockop, MD, Andromachi Scaradavou, MD, Trudy N. Small, MD, Hugo Castro-Malaspina, MD, Richard J. O’Reilly, MD
Journal: Blood
Blood (2007) 110 (11): 2991.
https://doi.org/10.1182/blood.V110.11.2991.2991
Published: 2007
Journal Articles

Induction of Remission Prior to Transplantation Improves the Disease-Free Survival (DFS) of Patients with Advanced Myelodysplastic Syndromes (MDS) Treated with Myeloablative T - Cell Depleted (TCD) Stem Cell Transplants (SCT) from Histocompatible Unrelated Donors.

H.R. Castro-Malaspina, MD, Ann A. Jakubowski, M.D., Esperanza B. Papadopoulos, M.D., Farid Boulad, M.D., James W. Young, M.D., Nancy A. Kernan, M.D., Miguel-Angel Perales, M.D., Trudy N. Small, M.D., Michelle Chiu, Glenn Heller, Ph.D., Marcel Van Den Brink, M.D., Stephen D. Nimer, M.D., Richard J. O’Reilly, M.D.
Journal: Blood
Blood (2006) 108 (11): 4859.
https://doi.org/10.1182/blood.V108.11.4859.4859
Published: 2006
Journal Articles

Induction of Remission Prior to Transplantation Improves the Disease-Free Survival (DFS) of Patients with Advanced Myelodysplastic Syndromes (MDS) Treated with Myeloablative T-Cell Depleted (TCD) Stem Cell Transplants (SCT) from HLA Identical Siblings.

H.R. Castro-Malaspina, MD, Ann A. Jakubowski, MD, Esperanza B. Papadopoulos, MD, Farid Boulad, MD, James W. Young, MD, Nancy A. Kernan, MD, Miguel A. Perales, MD, Trudy N. Small, MD, Katharina C. Hsu, MD, Michelle Chiu, Glenn Heller, PhD, Marcel van den Brink, MD, Stephen D. Nimer, MD, Richard J. O’Reilly, MD
Journal: Blood
Blood (2005) 106 (11): 5426.
https://doi.org/10.1182/blood.V106.11.5426.5426
Published: 2005